title: Melanoma patients respond to a new HLA-A*01-presented antigenic ligand derived from a multi-epitope region of melanoma antigen TRP-2.
abstract: Tyrosinase-related protein-2 (TRP-2) is a known target antigen of spontaneous cytotoxic T cell responses in melanoma patients. Its frequent expression in metastatic tumors suggests that it might be an ideal candidate antigen for T cell-based immunotherapy. To provide knowledge about TRP-2-derived T cell epitopes useful for immunotherapy we applied a "reverse immunology strategy" based on repeated in vitro peptide stimulation of peripheral blood lymphocytes (PBL) from normal donors with predicted HLA-A*01 ligands. This led to the identification of TRP-2(181-190) as the first HLA-A*01-presented TRP-2-derived epitope. T-cell lines specific for peptide TRP-2(181-190) could be established from PBL of 50% of the normal HLA-A*01(+) donors tested. Such T cells responded specifically to autologous dendritic cells transduced virally with TRP-2, as well as to HLA-A*01(+), TRP-2(+) melanoma cells, although tumor cells had to be pretreated with IFN-gamma to become susceptible to T cell recognition. Interestingly, short-term in vitro peptide stimulation of PBL from HLA-A*01(+) melanoma patients showed the presence of TRP-2(181-190)-reactive CD8(+) T cells in some donors, suggesting their in vivo sensitization. Because TRP-2(181-190) overlaps with the known HLA-A*0201-presented epitope TRP-2(180-188), an 11mer peptide encompassing both epitopes might be of specific value for vaccination of a broad population of melanoma patients.
authors.affiliation: Skin Cancer Unit of the German Cancer Research Center at the University Hospital of Mannheim, Mannheim, Germany. a.paschen@dkfz.de
authors.forename: Annette
authors.initials: A
authors.lastname: Paschen
authors.forename: Weiqing
authors.initials: W
authors.lastname: Jing
authors.forename: Ingo
authors.initials: I
authors.lastname: Drexler
authors.forename: Moritz
authors.initials: M
authors.lastname: Klemm
authors.forename: Mingxia
authors.initials: M
authors.lastname: Song
authors.forename: Jan
authors.initials: J
authors.lastname: Müller-Berghaus
authors.forename: Xuan Duc
authors.initials: XD
authors.lastname: Nguyen
authors.forename: Wolfram
authors.initials: W
authors.lastname: Osen
authors.forename: Stefan
authors.initials: S
authors.lastname: Stevanovic
authors.forename: Gerd
authors.initials: G
authors.lastname: Sutter
authors.forename: Dirk
authors.initials: D
authors.lastname: Schadendorf
mesh_terms: D000595:Amino Acid Sequence; D003713:Dendritic Cells / Q000276:immunology; D000939:Epitopes / Q000032:analysis / Q000737:chemistry; D015234:HLA-A Antigens / Q000276:immunology*; D015788:HLA-A1 Antigen; D006801:Humans; D007167:Immunotherapy; D019746:Intramolecular Oxidoreductases / Q000737:chemistry / Q000276:immunology*; D008024:Ligands; D008545:Melanoma / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D000939:Epitopes; D015234:HLA-A Antigens; D015788:HLA-A1 Antigen; D008024:Ligands; D019746:Intramolecular Oxidoreductases; C042501:dopachrome isomerase